BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28222668)

  • 1. Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Ryu HS; Lee EJ; Chun M
    Tumour Biol; 2017 Feb; 39(2):1010428317694306. PubMed ID: 28222668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
    Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
    Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy.
    Lee HJ; Kim JM; Chin YJ; Chong GO; Park SH; Lee YH; Hong DG; Lee YS
    Anticancer Res; 2020 Jan; 40(1):451-458. PubMed ID: 31892600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of haematologic parameter changes during treatment in cervical cancer patients treated with definitive chemoradiotherapy.
    Yildirim BA; Guler OC; Kose F; Onal C
    J Obstet Gynaecol; 2019 Jul; 39(5):695-701. PubMed ID: 31023114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
    Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
    Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
    Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
    Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Chun M
    Anticancer Res; 2017 Jan; 37(1):327-334. PubMed ID: 28011510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
    Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
    Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study.
    Landoni F; Sartori E; Maggino T; Zola P; Zanagnolo V; Cosio S; Ferrari F; Piovano E; Gadducci A
    Gynecol Oncol; 2014 Mar; 132(3):611-7. PubMed ID: 24342439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
    Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
    Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA).
    Lee YY; Choi CH; Kim CJ; Song TJ; Kim MK; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
    Gynecol Oncol; 2010 Mar; 116(3):459-63. PubMed ID: 20004008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
    Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
    J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
    Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
    Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.